osimertinib news - Search News

Drug extends survival in lung cancer patients

Combination extends survival vs. standard first-line therapy for advanced lung cancer

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with amivantamab-vmjw (Rybrevant,

Becker's Hospital Review · 2d

Drug extends survival in lung cancer patients: J&J

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.

Business Insider · 3d

Johnson & Johnson’s rybrevant plus lazcluze improve survival in lung cancer

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from

CNBC on MSN · 3d

J&J says its lung cancer drug combination keeps people alive longer

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to supplant AstraZeneca's blockbuster Tagrisso,

J&J says cancer drug combination showed survival benefit over Tagrisso

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.

Oncology Nurse Advisor7h

Risk of Cardiac Events Higher With Osimertinib Than With Other TKIs

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

Hosted on MSN7h

Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

GlobalData on MSN2d

J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

9d

Esther Rantzen fought for ‘assisted dying’. Now she’s surely killed it off

The other day, Dame Esther Rantzen announced some wonderful news. In an article she’d written for a national newspaper, ...

4d

'Nonsense!' Dame Esther Rantzen hits back at assisted dying critic

Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.

oncnursingnews7d

Evaluating Targeted Therapies: MARIPOSA Trial Aids APPs in Treating EGFR+ NSCLC

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

8d

HUTCHMED's Combination Therapy For Lung Cancer Granted Priority Review By NMPA

Limited (HUTCHMED) (HCM) announced that the New Drug Application (NDA) for the combination of ORPATHYS(savolitinib) ...

European Commission approves Janssen-Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC

Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...

European Commission approves Janssen-Cilag International Rybrevant, Lazcluze combo for first-line treatment of lung cancer

Belgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results